Moteur de recherche d’entreprises européennes
Financement de l’UE (11,7 M €) : Scanner corporel total intelligent pour la détection précoce du mélanome Hor 05/02/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Scanner corporel total intelligent pour la détection précoce du mélanome
Melanoma is one of the most aggressive cancers that can be discovered at an early stage, and it is responsible for 60% of lethal skin neoplasia. Its incidence has been increasing in white population and could become a public health challenge because of an increase in life expectancy of the elderly population. Total body skin examination, the primary screening mechanism for melanoma, checks each pigmented skin lesion individually in search of typical melanoma signs. This can be a very time consuming technique for patients with atypical mole syndrome or a large number of naevi. iToBoS aims at developing an AI diagnostic platform for early detection of melanoma. The platform includes a novel total body scanner and a Computer Aided Diagnostics (CAD) tool to integrate various data sources such as medical records, genomics data and in vivo imaging. This approach will lead to a highly patient-tailored, early diagnosis of melanoma. The project will develop and validate an AI cognitive assistant tool to empower healthcare practitioners, offering a risk assessment for every mole. Beyond integrating all available information about the patient to personalise the diagnostic, it will provide methods for visualising, explaining and interpreting AI models, thus overcoming the “black box” nature of current AI-enabled CAD systems, and providing dermatologists with valuable information for their clinical practice. The new total body scanner will be based on an existing prototype developed by 3 of the project partners, but powered with high-resolution cameras equipped with liquid lenses. These novel lenses, based on two immiscible fluids of different refractive index, will allow achieving unprecedented image quality of the whole body. The integration of such images with all available patient data using machine learning will lead to a new dermoscopic diagnostic tool providing prompt, reliable and highly personalised diagnostics for optimal judgement in clinical practice.
| Barco N.V. | 215 186 € |
| Canfield Scientific GmbH | 394 008 € |
| Coronis Computing SL | 943 400 € |
| Ethnicon Metsovion Polytechnion | 436 500 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 810 713 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 1 003 029 € |
| Gottfried Wilhelm Leibniz Universitaet Hannover | 536 625 € |
| Hospital Clinic de Barcelona | 0,00 € |
| HUN-REN Szamitastechnikai ES Automatizalasi Kutatointezet | 323 750 € |
| IBM Israel - Science AND Technology Ltd. | 618 438 € |
| Isahit | 191 126 € |
| Melanoma Patient Network Europe | 167 531 € |
| Optotune Switzerland AG | 504 675 € |
| Ricoh Spain IT Services SL | 324 375 € |
| Robert Bosch Espana Fabrica Madrid SA | 2 117 820 € |
| Robert Bosch Espana SL | 0,00 € |
| THE University OF Queensland | 0,00 € |
| Torus Actions | 676 094 € |
| Trilateral Research Ltd. | 436 250 € |
| Universita Degli Studi Di Trieste | 396 250 € |
| Universitat de Girona | 1 128 875 € |
| V7 Ltd. | 458 438 € |
https://cordis.europa.eu/project/id/965221
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
